Aims to accelerate the commercialization of life science innovations and expand the Nevada biotech ecosystem
Roseman University of Health Sciences today announced the launch of Roseman Bioventures in Las Vegas to accelerate the translation of scientific breakthroughs into therapies and technologies that advance health.
Located on Roseman’s Summerlin campus, the 120,000-square-foot facility will serve as one of the largest dedicated life science incubators in the Intermountain West, providing startups and emerging companies with turnkey laboratories, research infrastructure, regulatory guidance and connections to investors and industry partners accelerating the path to commercialization.
“Our vision for Roseman Bioventures is rooted in world-class research facilities that bridge the gap between research and commercial success,” said Jeff Talbot, PhD, Roseman University’s vice president for research. “We are expanding the Las Vegas ecosystem to support Nevada’s next generation of biotech leaders.”
Roseman Bioventures is a natural progression from the university’s successful Bioscience Collaborative, which has already attracted companies including Heligenics, Regenicin, VenaVitals, and WAVR Technologies to the Summerlin campus. Roseman Bioventures has assembled a growing team of local and national leaders in life science venture capital, finance, legal, and entrepreneurship. Through these partnerships, including Frax Finance, Desert Forge Ventures, Nevada Governor’s Office of Economic Development, Las Vegas Global Economic Alliance, and BioTech Vegas, Roseman Bioventures aims to solidify Southern Nevada as the center for biotech entrepreneurship in the Intermountain region. J.P. Morgan is a supporting sponsor providing financial, banking and investment insights to member start-up companies.
“Opportunities for life science startups in Nevada are tremendous from a regulatory and financial operational perspective, and we are excited to be part of the growing biotech ecosystem,” said Sam Kazemian, CEO of Frax Finance.
The launch comes as the U.S. life sciences sector continues to expand beyond traditional coastal hubs. Nevada’s pro-business environment, no state income tax, and rapidly growing population have positioned the state as an emerging destination for life science investment and innovation.
According to Talbot, Compared to West and East Coast biotech corridors, Roseman Bioventures offers a cost advantage, making it an attractive incubator for early- to mid-stage life science companies.
“Access to investment opportunities is critical for a thriving life science startup ecosystem,” said Len Jessup, managing director of Desert Forge Ventures, a local venture capital enterprise that currently invests in several startups at Roseman Bioventures. “We look forward to continuing our close collaboration to make Southern Nevada a destination and foundry for life science technology and innovation, and to work with early-stage company founders to diversify and strengthen the region’s biotech community.”
